title: Toxicity and adverse effects of everolimus in the treatment of advanced nonsmall cell lung cancer pretreated with chemotherapy--Chinese experiences.
abstract: BACKGROUND
  There is not more treatment selection for advanced nonsmall-cell lung cancer (NSCLC) patients who had disease progression after two previous treatments. Everolimus is an oral inhibitor of the mammalian target of rapamycin pathway, which is aberrantly activated in NSCLC.
  
  
  METHODS
  Stage IV NSCLC patients, with one or multiple prior chemotherapy regimens, received everolimus 5-10 mg/day with or without chemotherapy until progression or unacceptable toxicity. The primary objective were toxicity of everolimus and overall disease control rate (DCR).
  
  
  RESULTS
  22 patients were enrolled. Common ≥ grade 3 events were stomatitis, dyspnea, vomiting, thrombocytopenia. Overall disease control rate was 54.5% among 22 patients, 1 had a partial response, and 11 had disease stabilization. Common ≥ Grade 3 events were stomatitis, dyspnea, vomiting, and thrombocytopenia.
  
  
  CONCLUSIONS
  Everolimus was well tolerated, showing the modest clinical activity in heavily pretreated advanced NSCLC.
authors.forename: Y
authors.initials: Y
authors.lastname: Ju
authors.affiliation: Department of Oncology, Chinese PLA General Hospital, Beijing, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Hu
authors.forename: S
authors.initials: S
authors.lastname: Sun
authors.forename: J
authors.initials: J
authors.lastname: Wang
authors.affiliation: Department of Oncology, Chinese PLA General Hospital, Beijing, China.
authors.forename: S
authors.initials: S
authors.lastname: Jiao
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D044466:Asian People; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000378:metabolism; D018450:Disease Progression; D000068338:Everolimus / Q000009:adverse effects* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D058570:TOR Serine-Threonine Kinases / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D000068338:Everolimus; D058570:TOR Serine-Threonine Kinases